Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Enrolling by invitation Not applicable

Preventive Remediation for OptiMal StudentS (PROMESS-Group)

NCT07030751 · tracked via the Priya Life Science France tracker
Sponsor
Research on Healthcare Performance Lab U1290
Phase
Not applicable
Started
2025-02-18
Last updated
2026-01-12

Condition(s) studied

Health BehaviorHealth-Related Behavior

Investigational drug(s) / intervention(s)

Stress management, sleep improvement and fatigue reduction, sedentary behaviors reduction and physical activity promotion.

Stress management, sleep improvement and fatigue reduction, sedentary behaviors reduction and physical activity promotion.: The study seeks to quantify the impact of a complex intervention based on 3 modules : 1. Stress management 2. Sleep improvement and fatigue reduction, 3. Sedentary behaviors reduction and physical activity promotion. Students from the interventional group will follow these 3 different health-related modules in a specific order (stress, sleep, physical activity). Each module will be composed of 3 sessions. Each session includes individual interviews covering initial assessment and personalized goal setting.

Study summary

Health students exhibit excessive sedentary behavior, elevated stress levels, and significant sleep disturbances, all of which contribute to a decline in their overall health, quality of life, and learning capacities.

The PROMESS-Group project (Preventive Remediation for OptiMal StudentS-Group) is a multimodal intervention targeting stress management, sleep improvement, and physical activity enhancement, with the aim of improving students' quality of life throughout their academic journey.

Encouraging physical activity, reducing sedentary behaviors, reducing stress, fatigue and sleep troubles during their curriculum can promote a healthier lifestyle and reduce the risk of chronic health conditions in the future.

The study seeks to quantify the impact of a complex intervention based on 3 modules (stress, sleep, physical activity) on the quality of life of health students. This study will also have a clear insight on the influence of the complex intervention on changes in stress, sleep, physical activity and sedentary behavior markers.

Eligibility

Sex
ALL
Min age
18 Years
Max age
80 Years
Healthy volunteers
Accepted
Inclusion Criteria: * Being a 4th- or 5th-year medical student enrolled at the Faculty of Medicine (Lyon Est or Lyon Sud), or a PhD student registered in Lyon's health-related doctoral schools during the 2024-2025 or 2025-2026 academic years * Having read the information note * Having signed the written consent Exclusion Criteria: * Student who did not provide consent * Non-French-speaking student

Primary outcome measure(s)

  • Quality of life. Change from pre-intervention in a composite score obtained at the Brief Quality Of Life questionnaire at the post-interventional measure at Week 16. — Week 1 (Pre-intervention) and Week 16 (Post-intervention)
    The students level of the quality of life is assessed four sub-scores of quality of life (i.e. physical health, psychic well-being, social relationship, environnement). The composite score is the mean of the 2 dimensions: physical health and psychological well-being. The measure will be done at different time frame: 1. Pre-intervention measure at week 1: before any involvement in the intervention (for the control and interventional groups). 2. Post-intervention measure at week 16 : after the intervention (for the control and interventional groups). * Change = (Week 16 score - Week 1 score) Evolution of the 4 subscores will also be analyzed independantly.

Trial sites (1)

FacilityCityRegionStatus
Research on Healthcare Performance Lab U1290 Lyon France

More Research on Healthcare Performance Lab U1290 trials in France

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07030751 on ClinicalTrials.gov ↗ ← All trials in France